EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Targeting the Unmet Need in Gastrointestinal Stromal Tumors: A Contemporary Review of Investigational Clinical Trials and Therapeutic Landscape

Andrej Belančić iD, Juraj Prejac iD, Marin Golčić iD, Gordan Adžić, Andrija Katić, Lidija Kocić, Anamarija Kovač Peić, Nikša Librenjak iD, Borislav Belev, Ivana Mikolašević, Stjepko Pleština

Pharmaceuticals · 29.03.2026 · 19 (4) · 548

DOI: 10.3390/ph19040548 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 29.03.2026. Verfasst von Andrej Belančić und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Basic and Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Rijeka, 51000 Rijeka, Croatia. Die Arbeit nennt 91 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasms of the gastrointestinal tract and are primarily driven by activating mutations in KIT or PDGFRA. Although tyrosine kinase inhibitors (TKIs), particularly imatinib, have substantially improved outcomes, most patients with advanced disease eventually develop resistance, resulting in disease progression.

Methods

We performed a narrative review with scoping approach of interventional clinical trials registered on ClinicalTrials.gov between January 2020 and July 2025 to characterize the contemporary investigational therapeutic landscape in GIST. Eligible studies included clinical trials evaluating novel agents, combinations, or alternative strategies beyond current regulatory approvals. Trial characteristics, therapeutic classes, endpoints, enrollment, and funding sources were analyzed.

Results

A total of 27 ongoing trials were identified. Most studies were phase I/II and focused on metastatic or unresectable disease, predominantly in the second-line or later settings. TKIs remained the dominant therapeutic class, included in over 70% of trials, either as monotherapy or in combination. Emerging strategies comprised antibody–drug conjugates, immune checkpoint inhibitors, HIF inhibitors, FGFR inhibitors, and epigenetic modulators. Only four phase III trials were identified, reflecting the difficulty of conducting large, randomized studies in GIST. No trial used overall survival or quality of life as a primary endpoint.

Conclusions

The current investigational landscape in GIST is largely focused on overcoming TKI resistance in advanced disease. Molecular stratification and personalized approaches dominate ongoing research, but evidence generation remains limited by small sample sizes and slow recruitment. Future trials integrating innovative therapeutic platforms and patient-centered outcomes are essential to improve long-term disease control and quality of life.

Schlagwörter

Stichwörter der Autor:innen

clinical trialsgastrointestinal stromal tumourtargeted therapytyrosine kinase inhibitors

Autor:innen und Institutionen

  • Department of Basic and Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Rijeka, 51000 Rijeka, Croatia.
  • Department of Oncology, University Hospital Centre Zagreb, 10000 Zagreb, Croatia.
  • University of Zagreb, School of Dental Medicine, 10000 Zagreb, Croatia.
  • Tumor Clinic, Clinical Hospital Centre Rijeka, 51000 Rijeka, Croatia.
  • Department of Oncology and Radiotherapy, Faculty of Medicine, University of Rijeka, 51000 Rijeka, Croatia.
  • Department of Oncology and Radiotherapy, University Hospital Center Split, 21000 Split, Croatia.

ORCID-Profile: Andrej Belančić, Juraj Prejac, Marin Golčić, Nikša Librenjak

Zitieren

APA

Belančić, A., Prejac, J., Golčić, M., Adžić, G., Katić, A., Kocić, L., Kovač Peić, A., Librenjak, N., Belev, B., Mikolašević, I., & Pleština, S. (2026). Targeting the Unmet Need in Gastrointestinal Stromal Tumors: A Contemporary Review of Investigational Clinical Trials and Therapeutic Landscape. Pharmaceuticals, 19(4), 548. https://doi.org/10.3390/ph19040548

Vancouver

Belančić A, Prejac J, Golčić M, Adžić G, Katić A, Kocić L, et al. Targeting the Unmet Need in Gastrointestinal Stromal Tumors: A Contemporary Review of Investigational Clinical Trials and Therapeutic Landscape. Pharmaceuticals. 2026;19(4):548. doi:10.3390/ph19040548

BibTeX
@article{Belani2026,
  author = {Belančić, Andrej and Prejac, Juraj and Golčić, Marin and Adžić, Gordan and Katić, Andrija and Kocić, Lidija and Kovač Peić, Anamarija and Librenjak, Nikša and Belev, Borislav and Mikolašević, Ivana and Pleština, Stjepko},
  title = {Targeting the Unmet Need in Gastrointestinal Stromal Tumors: A Contemporary Review of Investigational Clinical Trials and Therapeutic Landscape},
  journal = {Pharmaceuticals},
  year = {2026},
  volume = {19},
  number = {4},
  pages = {548},
  doi = {10.3390/ph19040548}
}
Kostenlos starten →